Efficacy and Safety of Oral Octreolin™ in Patients With Acromegaly Who Are Currently Receiving Parenteral Somatostatin Analogs

Trial Profile

Efficacy and Safety of Oral Octreolin™ in Patients With Acromegaly Who Are Currently Receiving Parenteral Somatostatin Analogs

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Octreotide (Primary)
  • Indications Acromegaly
  • Focus Registrational; Therapeutic Use
  • Sponsors Chiasma
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 31 Aug 2015 According to a Chiasma media release, the agency has set a target review date under the Prescription Drug User Fee Act (PDUFA) of April 15, 2016.
    • 17 Aug 2015 According to a Chiasma media release, the U.S. FDA has accepted for filing the company's NDA for octreotide capsules for the maintenance therapy of adult patients with acromegaly.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top